Novel Drug Delivery System Market Becomes a Drug-Lifecycle Platform as Long-Acting Injectables and AI Formulation Reduce Dosing Burden

NEW YORK, July 31, 2026 - The global Novel Drug Delivery System Market reached US$ 22.3 billion in 2025 and is expected to reach US$ 73.8 billion by 2033, growing at a CAGR of 21.2% during the forecast period 2026-2033, according to DataM Intelligence. North America currently leads the market, while Asia-Pacific is expected to record the fastest growth.

Drug delivery is no longer a supporting step performed after a molecule has been selected. It increasingly determines how often a medicine must be taken, where it can be administered, how consistently it reaches its target and whether it can remain commercially differentiated as competition increases.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/novel-drug-delivery-system-market?kailas

Long-acting injectables illustrate this shift clearly. A medicine that previously required daily or weekly dosing may be redesigned to release its active ingredient over several weeks or months. That change can affect adherence, treatment continuity, manufacturing requirements, intellectual-property strategy and the economics of commercialization.

2026 Development in Long-Acting Injectable Formulation Intelligence

A study first released on January 5, 2026 applied explainable machine learning to 321 polymer-based long-acting injectable formulations. The researchers developed models to predict early drug release at 24, 48 and 72 hours, classify release-profile patterns and estimate complete release curves.

The model achieved a correlation above 0.65 for predicted drug release at 72 hours and an F1 score of 0.87 when classifying release-profile types. The study also used Shapley-based explanations to identify which material characteristics had the strongest influence on release behaviour.

This does not remove the need for laboratory testing, stability studies or clinical development. It gives formulation teams a better way to screen material combinations, interpret failed experiments and narrow the number of formulations that must be tested physically.

Long-acting injectable development has traditionally involved repeated adjustments to polymer composition, particle size, drug loading and manufacturing conditions. Explainable models can help scientists understand why a formulation is likely to show an initial burst, delayed release or an incomplete release profile rather than presenting only a numerical prediction.

PrecisionSphere Moves From Platform Promise to Commercial Validation

Lupin's PrecisionSphere program provides a commercial example of how a proprietary drug-delivery platform can become a licensing and partnership asset.

PrecisionSphere was developed by Lupin subsidiary Nanomi B.V. using a proprietary Microsieve process. The technology is designed to manufacture microspheres and nanoparticles with consistent size and shape, supporting more reproducible controlled release and injectability. Lupin describes the process as scalable and adaptable across different therapeutic requirements.

In September 2025, the US Food and Drug Administration approved Lupin's extended-release injectable risperidone, the first approved product developed through Nanomi's long-acting injectable platform. The formulation uses uniform microspheres to provide release over an extended period and received 180-day competitive generic therapy exclusivity.

Lupin subsequently launched a strategic partnership program for PrecisionSphere. The company is inviting collaborations with pharmaceutical businesses seeking longer-acting versions of medicines that are either under development or already commercialized. The partnership model combines formulation technology with regulatory experience, manufacturing capabilities and alliance-management support.

The program shows why drug delivery is becoming part of lifecycle strategy. A validated platform can be applied to several molecules, licensed to external partners and supported through commercial manufacturing rather than remaining limited to an internal research project.

Request a Customized Report According to Your Business Strategy: https://www.datamintelligence.com/customize/novel-drug-delivery-system-market?kailas

Growth Drivers Reshaping the Market

The rising use of biologics, peptides, nucleic-acid medicines and other complex therapies is creating demand for delivery systems that protect sensitive molecules and transport them to the required site of action.

Poor adherence is another major commercial issue. Treatments for neurological disorders, psychiatric conditions, diabetes and other chronic illnesses may lose effectiveness when doses are missed. Long-acting formulations can reduce the number of administration events and create more predictable drug exposure.

Pharmaceutical companies are also using controlled-release, targeted-delivery and device-assisted platforms to extend the commercial relevance of established products. Reformulation can support improved convenience, a new administration route, reduced dosing frequency or differentiation from standard generic versions.

However, delivery innovation introduces additional development risks. Formulators must address stability, sterility, viscosity, particle behaviour, scale-up, container compatibility and regulatory expectations. An attractive laboratory formulation may still fail if it cannot be manufactured consistently at commercial scale.

Novel Drug Delivery System Market Segmentation

By route of administration, the market includes oral, injectable, pulmonary, transdermal and other delivery systems. Oral products remain widely used because they are familiar and generally convenient, while injectable delivery is gaining importance for biologics, depot medicines and therapies requiring controlled systemic exposure.

By delivery mode, the market includes:
- Targeted drug delivery systems
- Controlled drug delivery systems
- Modulated drug delivery systems

Controlled-release systems regulate how quickly an active ingredient becomes available. Targeted systems are designed to concentrate treatment at a specific tissue, cell or biological pathway. Modulated systems adjust delivery in response to time, physiological conditions or an external trigger.

Major technologies include microspheres, nanoparticles, liposomes, lipid nanoparticles, hydrogels, micelles, transdermal patches, implantable systems and drug-device combinations.

By indication, the market covers oncology, infectious diseases, respiratory conditions, diabetes, cardiovascular diseases, autoimmune disorders and neurological diseases. Hospitals, specialty clinics, ambulatory facilities, home-care environments and research institutions represent the main end-user groups.

United States and Japan Regional Analysis

The United States leads the market through its concentration of pharmaceutical developers, biotechnology companies, specialist CDMOs, device manufacturers and regulatory expertise. The approval of Lupin's extended-release risperidone also provides a practical reference for companies evaluating microsphere-based long-acting injectable programs.

US opportunities are likely to concentrate on platform licensing, complex generics, biologics delivery, combination products and formulations that can move suitable treatments into less resource-intensive care settings.

Japan represents an important market because of its advanced pharmaceutical industry, aging population and demand for therapies that simplify long-term treatment. Japanese companies have established capabilities in formulation science, polymers, medical devices and precision manufacturing.

Long-acting formulations may be particularly relevant where repeated hospital visits or complex dosing schedules create a burden for patients and healthcare systems. Commercial success in Japan will depend on local clinical evidence, regulatory planning, manufacturing quality and delivery formats suited to domestic treatment practices.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=novel-drug-delivery-system-market?kailas

Company Profiles

Lupin

Lupin is commercializing its PrecisionSphere platform through its Nanomi subsidiary. The platform uses controlled microsphere production to support consistent drug release over periods ranging from weeks to months. Lupin has moved the technology through US regulatory approval, commercial launch and external partnership development, creating a model that connects formulation, manufacturing and licensing.

Alkermes

Alkermes has established long-acting injectable capabilities through technologies including Medisorb, LinkeRx and NanoCrystal. These platforms are designed to provide controlled release of small molecules and complex macromolecules. The company has also licensed proprietary technologies for medicines developed or commercialized by external partners, demonstrating the continuing value of platform-based drug delivery.

Evonik

Evonik provides excipients, formulation services and CDMO support across oral, parenteral and next-generation drug-delivery applications. Its parenteral portfolio covers bioresorbable polymers, polymer microparticles, lipid nanoparticles, in-situ gelling systems and drug-eluting implants. The company supports projects from formulation development and scale-up through GMP manufacturing and commercial supply.

BD

BD Medical-Pharmaceutical Systems develops prefillable syringes, self-injection systems and connected delivery technologies for pharmaceutical and biotechnology companies. Its portfolio supports medicines across different volumes, viscosities and therapeutic areas, while its services cover testing, verification, regulatory support and combination-product readiness.

The next phase of the Novel Drug Delivery System Market will be shaped by platforms that can prove more than scientific novelty. Developers will need reproducible formulation performance, scalable production, regulatory acceptance and a clear commercial reason for changing the delivery profile.

DataM Intelligence's market analysis supports modality assessment, platform comparison, licensing evaluation, formulation benchmarking and manufacturing-opportunity analysis for companies developing long-acting injectables, controlled-release medicines and next-generation delivery technologies.

Read Exclusive Report Description: https://www.datamintelligence.com/research-report/novel-drug-delivery-system-market

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a global market research and business intelligence firm delivering actionable insights across healthcare, pharmaceuticals, chemicals, energy, technology, food, and industrial sectors. Through syndicated reports, custom research, consulting, and competitive intelligence services, the company helps organizations identify growth opportunities, navigate market challenges, and make informed strategic decisions in over 50+ countries worldwide.

This release was published on openPR.